Journal of Surgery Concepts & Practice >

2021 , Vol. 26 >Issue 04: 336 - 342

DOI: https://doi.org/10.16139/j.1007-9610.2021.04.011

Original article

Expression of B7S1 related with immune infiltration in colorectal cancer

Expand
  • 1. Department of General Surgery, Ruijin Hospital（North）, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China
    2. Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    3. Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University, Shanghai, 200011, China

Received date: 2021-04-19

  Online published: 2022-08-02

Fold

Abstract

Objective To investigate the expression of B7S1 mRNA which is encoded by VTCN1 and protein levels in colorectal cancer(CRC) with the analysis of relation to clinicopathological characteristics, immune cell infiltration, and prognosis for the evaluation as a immunotherapeutic target in CRC. Methods Both Oncomine and TIMER databases were used to review the expression of VTCN1 in a variety of human solid tumors. The relationship between the expression of VTCN1 and the clinicopathological characteristics of CRC was analyzed using UALCAN and LinkedOmics databases. The expression of VTCN1 which is related with immune infiltration and clinical prognosis was evaluated using Human Protein Atlas database, Kaplan-Meier Plotter and TIMER database. A total of 24 patients with CRC in Ruijin Hospital (North) were collected and the expression of B7S1 protein in both CRC and normal intestinal tissues was detected by immunofluorescence staining. Results It was found in database that VTCN1 was expressed in many human solid tumors. VTCN1 was highly expressed in various subtypes of CRC when compared with that in normal intestinal tissues. The up-regulated VTCN1 was related to tumor stage, lymph node metastasis, distant metastasis, mismatch repair and overall survival rate. VTCN1 was also related to the immune cell infiltration. Immunofluorescence analysis showed that the protein of B7S1 was up-regulated in CRC when compared with that in normal intestinal tissues, and it was expressed in CD45- cells and CD45+ cells. Conclusions As co-inhibitory immune checkpoint molecule, B7S1 may be a potential prognostic factor and might become the target of immunotherapy for CRC.

Key words： Colorectal cancer; B7S1; Immune checkpoint; Immune microenvironment; Tumor-infiltrating lymphocyte

Cite this article

WANG Changgang, LIU Kun, FENG Haoran, JIANG Yimei, SHI Yiqing, CHEN Xianze, SONG Zijia, LI Jun, LI You, CAI Dongli, ZHAO Ren . Expression of B7S1 related with immune infiltration in colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2021 , 26(04) : 336 -342 . DOI: 10.16139/j.1007-9610.2021.04.011

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Xie S, Huang J, Qiao Q, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors[J]. Cancer Immunol Immunother, 2018, 67(11):1685-1694.
[3] Overman MJ, Lonardi S, Wong KYM, et al. Durable cli-nical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8):773-779.
[4] Tang J, Jiang W, Liu D, et al. The comprehensive mole-cular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability[J]. Oncoimmunology, 2018, 7(10):e1488566.
[5] Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer[J]. Semin Cancer Biol, 2018, 52(Pt 2):189-197.
[6] Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3):434-452.
[7] Sharpe AH, Freeman GJ. The B7-CD28 superfamily[J]. Nat Rev Immunol, 2002, 2(2):116-126.
[8] Cai D, Li J, Liu D, et al. Tumor-expressed B7-H3 media-tes the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy[J]. Cell Mol Immunol, 2020, 17(3):227-236.
[9] Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6):361-375.
[10] Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2018, 17(4):258-273.
[11] Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE. B7-H3 immune checkpoint protein in human cancer[J]. Curr Med Chem, 2020, 27(24):4062-4086.
[12] Li J, Lee Y, Li Y, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells[J]. Immunity, 2018, 48(4):773-786.
[13] Prasad DV, Richards S, Mai XM, et al. B7S1, a novel B7 family member that negatively regulates T cell activation[J]. Immunity, 2003, 18(6):863-873.
Options
Outlines

/

〈 〉